Spots Global Cancer Trial Database for bone mineral density
Every month we try and update this database with for bone mineral density cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| The Safety and Efficacy of Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss | NCT00375505 | Breast Cancer | Zoledronic acid Placebo | 18 Years - | Novartis | |
| Vitamin D and Physical Activity on Bone Health | NCT01419730 | Bone Metabolism... Bone Mineral De... Physical Fitnes... | Vitamin D3 Physical Activi... | 18 Years - 99 Years | University of Rochester | |
| Strategies to Improve Bone Health in Men on ADT | NCT02043236 | Prostate Cancer | Healthy bones p... Bone Health Car... Letter to GP | 50 Years - | University Health Network, Toronto | |
| Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer | NCT00489905 | Prostatic Neopl... Bone Density | Zolderonic acid... | 50 Years - 80 Years | Hospital Authority, Hong Kong | |
| Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer | NCT00587925 | Breast Cancer Osteoporosis | Bone Mineral De... | - | Memorial Sloan Kettering Cancer Center | |
| A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer | NCT00171704 | Hormone Sensiti... | Letrozole Tamoxifen | 50 Years - | Novartis | |
| An Open Label Non-Interventional Evaluation of the Effect of Adjuvant Hormonal Treatment of Postmenopausal Women Wih Early Breast Cancer With Aromatase Inhibitors on Bone Mineral Density and Bone Fracture Rate in Daily Practice | NCT00767585 | Breast Cancer Osteoporosis | 55 Years - 65 Years | AstraZeneca | ||
| Strategies to Improve Bone Health in Men on ADT | NCT02043236 | Prostate Cancer | Healthy bones p... Bone Health Car... Letter to GP | 50 Years - | University Health Network, Toronto | |
| Effect of Supplementation With ω-3 Fatty Acids, Vitamin D and Calcium in Patients With Acute Lymphoblastic Leukemia. | NCT05950204 | Acute Lymphobla... Vitamin d Defic... | ω-3 polyunsatur... | 5 Years - 17 Years | Coordinación de Investigación en Salud, Mexico | |
| Vitamin D and Physical Activity on Bone Health | NCT01419730 | Bone Metabolism... Bone Mineral De... Physical Fitnes... | Vitamin D3 Physical Activi... | 18 Years - 99 Years | University of Rochester | |
| The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy | NCT00063609 | Prostate Cancer | zoledronic acid | 18 Years - | Novartis | |
| 99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis | NCT02304757 | Differentiated ... Osteoporosis | 99Tc-MDP Fosamax | 45 Years - | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | |
| A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer | NCT00171704 | Hormone Sensiti... | Letrozole Tamoxifen | 50 Years - | Novartis | |
| Bone Mineral Density Status in Pediatric and Adolescent Survivors of Childhood Cancer With History of Bone Fracture | NCT02355340 | Bone Mineral De... Childhood Cance... | Dual energy x-r... Peripheral quan... | 8 Years - 20 Years | Dana-Farber Cancer Institute | |
| Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid | NCT00295646 | Breast Cancer | tamoxifen anastrozole zoledronic acid goserelin | 19 Years - 59 Years | Austrian Breast & Colorectal Cancer Study Group | |
| Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer | NCT03324932 | Breast Cancer | Denosumab Injec... | 20 Years - | Kyoto Prefectural University of Medicine | |
| Health After eaRly Menopause Due to Oophorectomy | NCT03835793 | Surgical Menopa... BRCA1 Mutation BRCA2 Mutation Cardiovascular ... Bone Mineral De... Cognitive Decli... Quality of Life Menopause Surgi... | CAC-score | 55 Years - | The Netherlands Cancer Institute | |
| Arimidex Bone Mass Index and Oral Bisphosphonates | NCT00809484 | Breast Cancer Bone Density | 18 Years - 80 Years | Hellenic Breast Surgeons Society | ||
| Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer | NCT00213980 | Breast Cancer | Zoledronate | 18 Years - | University of Wisconsin, Madison | |
| Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of Therapy | NCT00972959 | Multiple Myelom... | Bortezomib Zoledronic Acid Dexamethasone | 18 Years - | University of Athens | |
| Danish Osteoporosis Prevention Study | NCT00252408 | Osteoporosis | Hormone replace... | 45 Years - 58 Years | University of Aarhus | |
| Fosamax for Childhood Cancer Survivors | NCT00391404 | Osteoporosis | Alendronate Placebo | 15 Years - | Chinese University of Hong Kong | |
| Bone Mineral Density Status in Pediatric and Adolescent Survivors of Childhood Cancer With History of Bone Fracture | NCT02355340 | Bone Mineral De... Childhood Cance... | Dual energy x-r... Peripheral quan... | 8 Years - 20 Years | Dana-Farber Cancer Institute | |
| The Safety and Efficacy of Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss | NCT00375505 | Breast Cancer | Zoledronic acid Placebo | 18 Years - | Novartis | |
| Fosamax for Childhood Cancer Survivors | NCT00391404 | Osteoporosis | Alendronate Placebo | 15 Years - | Chinese University of Hong Kong | |
| Retrospective Study of the Biomechanical Properties of Large Allografts | NCT00632294 | Bone Cancer | Tissue Sample | - | M.D. Anderson Cancer Center | |
| 99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis | NCT02304757 | Differentiated ... Osteoporosis | 99Tc-MDP Fosamax | 45 Years - | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | |
| Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy | NCT00582556 | Prostate Cancer | Zometa zometa Zometa | 18 Years - | University of Wisconsin, Madison | |
| Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy | NCT00485953 | Bone Loss Osteoporosis Breast Cancer | risedronate | 55 Years - | University of Pittsburgh | |
| A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer | NCT00171704 | Hormone Sensiti... | Letrozole Tamoxifen | 50 Years - | Novartis | |
| Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer | NCT00332709 | Osteoporosis Postmenopausal | Letrozole Zoledronic acid | 18 Years - | Novartis | |
| Velcade Consolidation Bone Study | NCT01286077 | Multiple Myelom... | bortezomib | 18 Years - | Janssen-Cilag International NV | |
| Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of Therapy | NCT00972959 | Multiple Myelom... | Bortezomib Zoledronic Acid Dexamethasone | 18 Years - | University of Athens | |
| A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis | NCT05862272 | Uterine Fibroid... Endometriosis | Relugolix Combi... | 18 Years - 50 Years | Sumitomo Pharma Switzerland GmbH | |
| HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer. | NCT00412022 | Breast Cancer | tamoxifen triptorelin letrozole zoledronic acid | 18 Years - | National Cancer Institute, Naples | |
| Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer | NCT00213980 | Breast Cancer | Zoledronate | 18 Years - | University of Wisconsin, Madison | |
| Effects of Zometa and Physical Activity on Bone Density in Women Receiving Chemotherapy for Breast Cancer | NCT00202059 | Breast Cancer | Zoledronic acid Physical activi... | 40 Years - 55 Years | HealthPartners Institute | |
| Effect of Supplementation With ω-3 Fatty Acids, Vitamin D and Calcium in Patients With Acute Lymphoblastic Leukemia. | NCT05950204 | Acute Lymphobla... Vitamin d Defic... | ω-3 polyunsatur... | 5 Years - 17 Years | Coordinación de Investigación en Salud, Mexico | |
| Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer | NCT00073073 | Breast Neoplasm... | Exemestane Calcium carbona... Vitamin D | - | Georgetown University | |
| A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss | NCT00333229 | Primary Hormone... | Zoledronic Acid Placebo | 18 Years - | Novartis | |
| High Impact Training to Patients With Prostate Cancer and Bone Metastases | NCT06259279 | Prostate Cancer | High intensity ... | 18 Years - | Copenhagen University Hospital at Herlev | |
| Vibration Intervention For Bone Enhancement In Childhood Cancer Survivors | NCT01010230 | Bone Mineral De... Bone Strength | LMHF mechanical... LMHF mechanical... | 7 Years - 17 Years | St. Jude Children's Research Hospital | |
| Study of Oral Bisphosphonate for Osteopenic Women Treated With Adjuvant Aromatase Inhibitors | NCT02616744 | Breast Cancer | Ibandronic acid Placebo | 18 Years - 75 Years | Azienda Ospedaliero-Universitaria Careggi | |
| A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss | NCT00333229 | Primary Hormone... | Zoledronic Acid Placebo | 18 Years - | Novartis | |
| Study of Oral Bisphosphonate for Osteopenic Women Treated With Adjuvant Aromatase Inhibitors | NCT02616744 | Breast Cancer | Ibandronic acid Placebo | 18 Years - 75 Years | Azienda Ospedaliero-Universitaria Careggi | |
| Arimidex Bone Mass Index and Oral Bisphosphonates | NCT00809484 | Breast Cancer Bone Density | 18 Years - 80 Years | Hellenic Breast Surgeons Society |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
